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AIH

:   autoimmune hepatitis

COVID‐19

:   coronavirus disease 2019

SARS‐CoV‐2

:   severe acute respiratory syndrome

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a pandemic infection causing coronavirus disease 2019 (COVID‐19), and Italy is one of the mostly affected countries worldwide.^(^ [^1^](#hep41557-bib-0001){ref-type="ref"} ^)^ The impact of COVID‐19 in patients with autoimmune liver disease treated with immunosuppressive therapy has not been described so far. Primarily, concerns have been raised for immunosuppressed patients, particularly those with autoimmune hepatitis (AIH), due to the possibility of decompensation of liver disease, or to an unfavorable course of SARS‐CoV‐2 infection. AIH is a rare liver disease and a prototypical example of chronic autoimmune condition requiring maintenance immunosuppression.^(^ [^2^](#hep41557-bib-0002){ref-type="ref"} ^)^ Stopping immunosuppression is associated with almost inevitable relapse of the disease.^(^ [^3^](#hep41557-bib-0003){ref-type="ref"} ^)^ Viral infections in an immunocompromised host are more frequent than in the general population, and have the ability to cause severe disease at much higher rates than in the healthy population.^(^ [^4^](#hep41557-bib-0004){ref-type="ref"}, [^5^](#hep41557-bib-0005){ref-type="ref"} ^)^ Nonetheless, data from previous outbreaks of Coronavirus infections, like severe acute respiratory syndrome and Middle East respiratory syndrome, did not report a higher risk of morbidity and mortality related to immunosuppression.^(^ [^6^](#hep41557-bib-0006){ref-type="ref"} ^)^ Therefore, there is uncertainty on how to manage immunosuppression therapy during the SARS‐CoV‐2 pandemic.

This report describes the clinical course of ten patients with AIH who developed COVID‐19 in Italy. Patients provided informed consent for the inclusion in this study, and the diagnostic procedures were conducted in accordance with institutional guidelines.

Case Series {#hep41557-sec-0002}
===========

We contacted 67 large Italian liver units (24 in Lombardy) during the outbreak of SARS‐CoV‐2, asking about cases of COVID‐19 that occurred in patients with AIH followed up at these centers.

Ten patients with AIH from seven different hospitals in Italy, located primarily in the Lombardy region, were diagnosed with COVID‐19 during the outbreak of SARS‐CoV‐2 in March 2020 (Table [1](#hep41557-tbl-0001){ref-type="table"}). Seven subjects were female (70%), and age ranged from 27 to 73 years. Cirrhosis was present in four cases (40%), and patient 6 had decompensated cirrhosis (Child‐Pugh B) with history of previous episodes of ascites and hepatic encephalopathy.

###### 

Clinical Course and Laboratory Results

  Patient ID                               1                                            2                      3              4               5                        6                       7                                            8                    9                                                       10
  ---------------------------------------- -------------------------------------------- ---------------------- -------------- --------------- ------------------------ ----------------------- -------------------------------------------- -------------------- ------------------------------------------------------- --------------------------------------------
  Age, years                               27                                           55                     45             55              53                       68                      55                                           65                   68                                                      73
  Sex                                      F                                            M                      F              M               F                        F                       F                                            M                    F                                                       F
  Cirrhosis                                Yes                                          No                     No             Yes             Yes                      Yes                     No                                           No                   No                                                      No
  Date of previous labs                    Feb 17, 2020                                 Feb 14, 2020           Jan 23, 2020   Mar 9, 2020     Mar 26, 2019             Mar 4, 2020             Feb 1, 2020                                  Mar 15, 2020         Feb 28, 2020                                            Feb 20, 2020
  AST, U/L                                 21                                           37                     22             317             34                       N/A                     37                                           19                   50                                                      27
  ALT, U/L                                 17.4                                         52                     24             497             36                       21                      19                                           14                   30                                                      16
  T Bil, mg/dl                             0.4                                          1.0                    1.0            2.6             1.0                      0.9                     1.6                                          0.6                  1.0                                                     N/A
  Alb, g/dl                                3.9                                          3.5                    4.2            3.0             3.7                      N/A                     4.3                                          N/A                  N/A                                                     3.9
  PLT, ×10^3^/μL                           146                                          255                    314            124             177                      93                      159                                          N/A                  N/A                                                     215
  Lymph, x10^9^/L                          N/A                                          N/A                    2.6            2.5             2.8                      N/A                     N/A                                          2.1                  N/A                                                     N/A
  IgG, g/L                                 14.0                                         10.0                   11.6           33.7            7.8                      N/A                     N/A                                          N/A                  N/A                                                     N/A
  P pre                                    Yes                                          Yes                    Yes            Yes             Yes                      Yes                     Yes                                          No                   Yes                                                     Yes
  Dose, mg                                 10                                           40                     10             60              10                       5                       5                                                                 25                                                      20
  AZA pre                                  Yes                                          Yes                    No             No              No                       No                      Yes                                          No                   No                                                      Yes
  Dose, mg                                 50                                           50                                                                                                     100                                                                                                                       75
  Other drugs for AIH                      Tac                                                                 No             No              No                       No                      No                                           MMF                  No                                                      No
  Dose                                     1 mg every 12 hours                                                                                                                                                                              1,500 mg/day                                                                 
  Clinical course                                                                                                                                                                                                                                                                                                        
  symptoms onset                           Mar 7, 2020                                  Mar 6, 2020            Mar 5, 2020    Mar 17, 2020    Mar 1, 2020              Mar 15, 2020            Mar 18, 2020                                 Mar 11, 2020         Mar 1, 2020                                             Feb 27, 2020
  Clinical features                        Cough, headache                              Fever                  Fever, cough   Fever, cough    Cough, fever, diarrhea   Cough, fever            Cough, fever                                 Fever, cough         Fever, ageusia                                          Fever, cough
  Swab positive for SARS‐CoV‐2             Yes                                          Yes                    Yes            Yes             Yes                      Yes                     Yes                                          Yes                  Yes                                                     Yes
  Managed at home or at hospital           Home                                         Hospital               Hospital       Hospital        Hospital                 Hospital                Home                                         Hospital             Home                                                    Home
  Pneumonia                                N/A                                          Yes                    Yes            Yes             No                       Yes                     N/A                                          Yes                  N/A                                                     N/A
  Respiratory failure                      No                                           No                     Yes            No              No                       Yes                     No                                           Yes                  No                                                      No
  Any change of drugs for AIH              Yes                                          Yes                    No             Yes             Yes                      Yes                     No                                           Yes                  Yes                                                     No
  If yes, which drug was changed?          P, Aza                                       P, Aza                                P               P                        P                                                                    MMF                  P                                                       
  Dose change                              P ↓ 7.5 mg/day, Aza X                        P ↓ 30 mg/day, Aza X                  P ↓ 40 mg/day   P ↑                      P ↑ 25 mg/day                                                        MMF ↓ 1,000 mg/day   Self‐stopped                                            
  Date of change                           Mar 15, 2020                                 Mar 7, 2020                           Mar 20, 2020    Mar 10, 2020             Mar 26, 2020                                                         Mar 26, 2020         Feb 3, 2020                                             
  Date of return to previous dose          Not yet                                      Not yet                               Not yet         Mar 23, 2020             Not yet                                                              Not yet              May 16, 2020[^†^](#hep41557-note-0005){ref-type="fn"}   
  Drugs for COVID‐19                       /                                            H, L/R, Azi            H, L/R         H, D/C          C, L/R                   H, L/R                  /                                            H, L/R, Azi          /                                                       /
  Repeated liver enzymes during COVID‐19   No[\*](#hep41557-note-0004){ref-type="fn"}   Yes                    Yes            Yes             Yes                      Yes                     No[\*](#hep41557-note-0004){ref-type="fn"}   Yes                  No[\*](#hep41557-note-0004){ref-type="fn"}              No[\*](#hep41557-note-0004){ref-type="fn"}
  AST, U/L                                                                              39                     23             82              98                       34                                                                   22                                                                           
  ALT, U/L                                                                              38                     17             101             46                       31                                                                   11                                                                           
  T Bil, mg/dL                                                                          1.5                    0.9            3.2             1.0                      0.8                                                                  0.7                                                                          
  Alb, g/dL                                                                             3.5                    3.6            2.6             3.4                      N/A                                                                  N/A                                                                          
  Lymph, x10^9^/L                                                                       N/A                    0.7            0.6             0.3                      N/A                                                                  0.5                                                                          
  Follow‐up labs                           Apr 27, 2020                                 May 19, 2020           Mar 20, 2020   Mar 26, 2020    Mar 18, 2020             No                      No                                           Apr 1, 2020          May 15, 2020                                            May 12, 2020
  AST, U/L                                 25                                           39                     30             66              36                                                                                            27                   600                                                     11
  ALT, U/L                                 34                                           39                     30             89              27                                                                                            14                   599                                                     17
  T Bil, mg/dL                             0.6                                          0.7                    N/A            2.2             1                                                                                             0.4                  2.4                                                     
  Alb, g/dL                                                                             37                     N/A            N/A             34                                                                                                                                                                         39
  Lymph, x10^9^/L                          1.6                                          3.5                    1.5            3.9             1.6                                                                                           1.0                  1.4                                                     
  Current status (as of May 21, 2020)      A                                            A                      A              A               A                        Exitus on Apr 1, 2020   A                                            A                    A                                                       A

SI conversion factors: to convert platelet count to ×10^9^ per liter, multiply by 1.

Blood exams not repeated due to restrictions related to compulsory quarantine at home.

Restarted with Prednisone 50 mg for the treatment of the relapse of AIH.

Abbreviations: A, asymptomatic; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Aza, azathioprine; Azi, azithromycin; C, chloroquine; D/C, darunavir/cobicistat; F, female; H, hydrochloroquine; IgG, Immunoglobulin G; L/R, lopinavir/ritonavir; Lymph, lymphocytes; M, male; MMF, mycophenolate; N/A, not applicable; P, prednisone; PLT, platelets; T Bil, total bilirubin; TAC, tacrolimus; Y, years.
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Before the onset of COVID‐19, all patients were taking immunosuppressive therapy with different dosages. All but one (patient 8) were on steroids (prednisone), and four (40%) were on azathioprine; patient 1 was on triple immunosuppressive regimen due to difficult‐to‐treat AIH. The immunosuppression regimen was stable in eight patients who were on biochemical remission at recent evaluation. Two other patients (patients 2 and 4) had an acute onset of AIH and were under high‐dose steroids, as per induction protocol, at the time of SARS‐CoV‐2 infection.

All cases were symptomatic for respiratory syndrome and positive for SARS‐CoV‐2 at nasal swab; four cases were managed at home under compulsory quarantine. Among those managed at home, one patient was afebrile and had persistent cough and headache; the others were febrile and had cough as main symptom. Among the six hospitalized subjects, five developed a computed tomography--confirmed COVID‐19 pneumonia. Three patients were treated with continuous positive airway pressure support for hypoxemic respiratory failure.

All subjects received a combination of an antiretroviral drug (either lopinavir/ritonavir or darunavir/cobicistat) with an antimalarial medication (either hydroxychloroquine or chloroquine); two cases were also treated with azithromicine. Empirical therapies for SARS‐CoV‐2 infection were in line with recommendations given by the infectious disease service of each hospital.

In seven patients, the dosage of immunosuppressive therapy was changed. Prednisone regimens were heterogeneously managed: in three cases doses were reduced, while patient 9 self‐stopped it. Patients 2 and 4 were given high‐dose corticosteroids to induce remission and tapering the dosage thereafter. In two cases, only the prednisone regimen was increased. Azathioprine was stopped in patients 1 and 2; in patient 1, prednisone was reduced from 10 mg/day to 7.5 mg/day, while tacrolimus was maintained at the same dose.

Liver enzymes were repeated during SARS‐CoV‐2 infection in all hospitalized cases, and remained within the normal range in all cases except for patients 2 and 4, in whom liver function tests dramatically improved. In four hospitalized cases, data about lymphocyte count were available; all patients experienced acute lymphopenia (severe in two subjects), which was not present before admission and fully reverted after COVID‐19.

At the time of submission, nine patients are still alive and asymptomatic, and patient 6 has died. Patient 9, who had previously self‐stopped immunosuppression with steroids, has experienced a relapse of AIH and is now being treated with prednisone 50 mg/day.

Discussion {#hep41557-sec-0003}
==========

We report here the first ten cases of COVID‐19 occurred in patients with AIH under immunosuppressive treatment. With the limitation of the short follow‐up and the lack of a control group of patients without AIH, we do report a somehow unremarkable COVID‐19 disease course despite ongoing immunosuppression. Remarkably, one patient went through COVID‐19 without developing pneumonia, despite the combination of compensated cirrhosis and acute AIH, with consequent need for high‐dose induction with steroids. The death event occurred in the frailest patient included in the cohort (patient 6), who already had decompensated cirrhosis, which is associated with significant morbidity and mortality.^(^ [^7^](#hep41557-bib-0007){ref-type="ref"} ^)^ Moreover, we believe that pre‐emptive strategies of reduction of immunosuppression during COVID‐19 can be potentially harmful, as suggested by the disease course of patient 9, who self‐stopped steroid treatment and relapsed after SARS‐CoV‐2 infection. There is growing evidence that part of the morbidity of COVID‐19 is due to the hyperinflammation and cytokine storm,^(^ [^8^](#hep41557-bib-0008){ref-type="ref"} ^)^ as supported by data from China, which showed that high levels of IL‐6 are associated with increased mortality^(^ [^9^](#hep41557-bib-0009){ref-type="ref"} ^)^ and the supposed beneficial effects of immunomodulators (tocilizumab and other IL‐6 blockers^(^ [^10^](#hep41557-bib-0010){ref-type="ref"} ^)^ such as baricitinib^(^ [^11^](#hep41557-bib-0011){ref-type="ref"} ^)^). Recently, a systems pharmacology--based network medicine platform identified mercaptopurine as one of the potential drugs to treat COVID‐19.^(^ [^12^](#hep41557-bib-0012){ref-type="ref"} ^)^ Mercaptopurine, also known as 6‐mercaptopurine, is a metabolite of azathioprine, and together with azathioprine belongs to the group of thiopurines, the most commonly used drugs for AIH maintenance. Thus, one could speculate that empirical strategies of reduction of immunosuppression in patients affected by chronic autoimmune diseases might be even harmful if immunosuppression might at least counterbalance COVID‐19‐driven hyperinflammation.

One of the known side effects of thiopurines is lymphopenia, which is often mild to moderate and considered a parameter of effective immunosuppression.^(^ [^13^](#hep41557-bib-0013){ref-type="ref"} ^)^ Yet, lymphopenia is known to predispose to viral infections, and thiopurines have been linked with increased incidence of opportunistic viral infections in patients with inflammatory bowel disease.^(^ [^4^](#hep41557-bib-0004){ref-type="ref"} ^)^ Data from the Wuhan experience have clearly shown that most patients with SARS‐CoV‐2 infection have lymphopenia,^(^ [^14^](#hep41557-bib-0014){ref-type="ref"} ^)^ and our data are in line with Chinese findings. The lack of a control group of patients without AIH and the nature of this manuscript (case series) do not allow us to draw conclusions regarding the possible association between chronic treatment with thiopurines and the risk of developing COVID‐19. Whether it would be sensible to stop thiopurines and increase steroids in patients with COVID‐19 treated with immunosuppression is difficult to be ascertained, and more evidence is needed. One should consider that it is highly likely that the immunosuppressive effect of thiopurines would not immediately cease after drug withdrawal, thanks to their mechanism of action,^(^ [^15^](#hep41557-bib-0015){ref-type="ref"} ^)^ while this is probably not true for steroids, as suggested by the early relapse occurred in case number 9. Moreover, there is well‐established literature showing that patients with AIH in stable control of their disease are at high risk of relapse when they suddenly reduce/stop their immunosuppression; therefore, empirical change of immunosuppressive medications should be considered with caution,^(^ [^3^](#hep41557-bib-0003){ref-type="ref"}, [^16^](#hep41557-bib-0016){ref-type="ref"} ^)^ before more evidence is available.

The main limitations of this study are the small sample size and the short follow‐up, which prevent us to infer whether patients with treated AIH have a specific clinical phenotype. To answer this research question, we would need a larger sample size and longer observation. In addition, the approach toward immunosuppression was too heterogenous to draw solid conclusions, especially regarding the beneficial or detrimental role of steroids during COVID‐19. Finally, this study does not allow us to understand whether patients with treated AIH are more or less prone to develop COVID‐19, lacking a non‐AIH control group. However, because COVID‐19 is a rapidly evolving epidemic that is affecting countries with different time frames, we believe our data are timely and could be of value for clinicians.

COVID‐19 in patients with AIH treated with immunosuppression appears to have a disease course presumptively similar to the general population. We believe that empirical reduction of immunosuppression in patients with AIH (and, by extension, other autoimmune conditions) during COVID‐19 might be harmful, as it could expose individuals to a higher risk of relapse of the disease.^(^ [^3^](#hep41557-bib-0003){ref-type="ref"} ^)^ Moreover, for most immunosuppressive drugs, the immunosuppressant effect would take weeks before disappearing. Up until now, a case‐by‐case approach is warranted, adopting clinical judgement until more data are collected and can guide the management of these challenging cases.
